1-14 of 14
Clemens M. Wendtner, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Kirsten Fischer, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Mark Dixon, BSc MSC, Jasmin Bahlo, Simon Warburton, MSc, Thomas J. Kipps, MD, PhD, Robert Weinkove, MD PhD, Sue Robinson, MD, Martin H. Dreyling, MD PhD, Stephen Opat, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Javier López, MD PhD, Kathryn Humphrey, PhD, Rod A. Humerickhouse, MD, Eugen Tausch, Barbara Eichhorst, MD, Clemens-M. Wendtner, MD, Anton W. Langerak, Jacques J.M. van Dongen, MD PhD, Matthias Ritgen, Sebastian Boettcher, MD, Stephan Stilgenbauer, Valentin Goede, MD, Mehrdad Mobasher, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2054.
https://doi.org/10.1182/blood.V128.22.2054.2054
Published: 2016
Journal Articles

Head-To-Head Comparison Of Obinutuzumab (GA101) Plus Chlorambucil (Clb) Versus Rituximab Plus Clb In Patients With Chronic Lymphocytic Leukemia (CLL) and Co-Existing Medical Conditions (Comorbidities): Final Stage 2 Results Of The CLL11 Trial

Valentin Goede, MD, Kirsten Fischer, MD, Raymonde Busch, PhD, Anja Engelke, Barbara Eichhorst, MD, Clemens M Wendtner, MD, Tatiana Chagorova, MD, Javier De la Serna, MD, PhD, Marie-Sarah Dilhuydy, MD, Stephen Opat, MD, Carolyn J. Owen, MD, FRCPC, Olga Samoylova, MD, Karl-Anton Kreuzer, MD, Anton W Langerak, PhD, Matthias Ritgen, MD, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Elina Asikanius, Kathryn Humphrey, Michael K Wenger, MD, Michael Hallek, MD
Journal: Blood
Blood (2013) 122 (21): 6.
https://doi.org/10.1182/blood.V122.21.6.6
Published: 2013
Journal Articles

Final Results of a Phase Ib Trial of Atacicept to Neutralize APRIL and BLyS in Patients with Refractory or Relapsed Chronic Lymphocytic Leukemia (CLL).

David M Kofler, MD, Barbara B Gawlik, MD, Thomas Elter, MD, Athos Gianella-Borradori, MD, Clemens M Wendtner, MD, Michael Hallek, MD
Journal: Blood
Blood (2009) 114 (22): 2373.
https://doi.org/10.1182/blood.V114.22.2373.2373
Published: 2009
Journal Articles

CD28 Costimulation of Effector T Cells During An Anti-Tumor Attack Sustains Its Repression by Regulatory T Cells Which Can Be Overcome by Preventing Lck Activation.

David M Kofler, MD, Markus Chmielewski, PhD, Tobias Riet, Andreas Hombach, MD, Michael Hallek, MD, Clemens M Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2009) 114 (22): 3569.
https://doi.org/10.1182/blood.V114.22.3569.3569
Published: 2009
Journal Articles

The Performance of Computed Tomography (CT) Scans or Ultrasound Has No Clinical Relevance in Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): Results of a Metaanalysis from Three Phase III Studies of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Kirsten Fischer, MD, Anna- Maria Fink, MD, Thomas Elter, MD, Clemens M Wendtner, MD, Raymonde Busch, Dipl., math., Michael Hallek, German CLL Study Group
Journal: Blood
Blood (2008) 112 (11): 1053.
https://doi.org/10.1182/blood.V112.11.1053.1053
Published: 2008
Journal Articles

Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.

Clemens M Wendtner, MD, Daruka Mahadevan, MD, PhD, Stephan Stilgenbauer, MD, PhD, Olga Frankfurt, MD, Adrian Bloor, PhD, MRCP, FRCPath, Francesc Bosch, MD, PhD, Lutz Uharek, Richard R Furman, MD, Marco Gobbi, John G. Gribben, MD, DSc, Eva K. Kimby, MD, PhD, Mikkael A. Sekeres, MD, MS, Larry D. Cripe, MD, Elyane Lombardy, Sheetal Shah, Laure A Moutouh-de Parseval, Asher Alban Chanan-Khan, MD, Robert D. Knight, MD
Journal: Blood
Blood (2008) 112 (11): 2104.
https://doi.org/10.1182/blood.V112.11.2104.2104
Published: 2008
Journal Articles

Statins Inhibit the Function of Human Antigen-Presenting Cells

Alexander Shimabukuro-Vornhagen, MD, Tanja Liebig, Shahram Zoghi, Clemens M Wendtner, MD, Michael S von Bergwelt-Baildon, MD
Journal: Blood
Blood (2008) 112 (11): 2560.
https://doi.org/10.1182/blood.V112.11.2560.2560
Published: 2008
Journal Articles

The Src-Abl Kinase Inhibitor Dasatinib (BMS-354825) Shows Anti-Proliferative and Anti-Apoptotic Effects in Chronic Lymphocytic Leukemia (CLL) Cells In Vitro .

Aditya Veldurthy, MSc, Michaela Patz, Dipl., Biol., Christian P. Pallasch, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, Gunter F. Krause, PhD
Journal: Blood
Blood (2007) 110 (11): 3101.
https://doi.org/10.1182/blood.V110.11.3101.3101
Published: 2007
Journal Articles

No Significant Clinical Benefit of First Line Therapy with Fludarabine (F) in Comparison to Chlorambucil (Clb) in Elderly Patients (pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Phase III Study of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Martina Stauch, MD, Manuela Bergmann, MD, Matthias Ritgen, MD, Nicole Kranzhöfer, MD, Carmen D. Schweighofer, MD, Kirsten Fischer, MD, Anna-Maria Fink, MD, Paula Cramer, Valentin Goede, MD, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG
Journal: Blood
Blood (2007) 110 (11): 629.
https://doi.org/10.1182/blood.V110.11.629.629
Published: 2007
Journal Articles

Impact of Regulatory T Cells on Antigen Specific T Cell Response Using Recombinant Chimeric T Cell Receptors In Vivo.

David M. Kofler, MD, Markus Chmielewski, Heike Koehler, Tobias Riet, Patrick Schmidt, Gunter Rappl, Andreas Hombach, MD, Michael Hallek, MD, Clemens M. Wendtner, MD, Hinrich Abken, MD
Journal: Blood
Blood (2006) 108 (11): 5475.
https://doi.org/10.1182/blood.V108.11.5475.5475
Published: 2006
Journal Articles

Overexpression of Lipases Enables Specific Cytotoxicity by the Lipase Inhibitor Orlistat in Chronic Lymphocytic Leukemia Cells.

Christian P. Pallasch, MD, Janine Schwamb, Alexandra Schulz, Svenja Debey, PhD, David Kofler, MD, Joachim L. Schultze, MD, Michael Hallek, MD, Alfred Ultsch, PhD, Clemens M. Wendtner, MD
Journal: Blood
Blood (2006) 108 (11): 2800.
https://doi.org/10.1182/blood.V108.11.2800.2800
Published: 2006
Journal Articles

CHOP Plus Rituximab (CHOP-R) in Fludarabine (F) Refractory Chronic Lymphocytic Leukemia (CLL) or CLL with Autoimmune Hemolytic Anemia (AIHA) or Richter’s Transformation (RT): First Interim Analysis of a Phase II Trial of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Ulrich Duehrsen, MD, Holger Schulz, MD, Clemens M. Wendtner, MD, Maria E. Goebeler, MD, Michael Hallek, MD, and GCLLSG
Journal: Blood
Blood (2005) 106 (11): 2126.
https://doi.org/10.1182/blood.V106.11.2126.2126
Published: 2005
Journal Articles

Comparison of the Efficacy and Toxicity of Fludarabine (F) in First Line Therapy of Younger Versus Elderly Patients (Pts) with Advanced Chronic Lymphocytic Leukemia (CLL): Results of a Meta-Analysis of Two Phase III Trials of the German CLL Study Group (GCLLSG).

Barbara F. Eichhorst, MD, Raymonde Busch, Clemens M. Wendtner, MD, Michael Hallek, MD, GCLLSG
Journal: Blood
Blood (2005) 106 (11): 717.
https://doi.org/10.1182/blood.V106.11.717.717
Published: 2005
Journal Articles

Consolidation with Alemtuzumab in First Remission Induces Pronounced MRD Reduction and Clinical Remissions - Update on a Randomized Phase III Trial of the German CLL Study Group (GCLLSG).

Matthias Ritgen, MD, C. Schweighofer, MD, Günther Fingerle-Rowson, MD, Barbara Eichhorst, MD, Raimunde Busch, Stephan Stilgenbauer, MD, Hartmut Döhner, MD, Michael Kneba, MD, PhD, Michael Hallek, MD, Clemens M. Wendtner, MD
Journal: Blood
Blood (2004) 104 (11): 2506.
https://doi.org/10.1182/blood.V104.11.2506.2506
Published: 2004